Anti-tumor effects of recombinant human cyclophilin A combined with immune checkpoint inhibitors in the experimental model of melanoma B16 in vivo

Introduction. Immune checkpoint inhibitors have an exceptional position in cancer immunotherapy. Currently, anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and anti-PD-1/PD-L1 (PD-1 – programmed cell death 1, PD-L1 – programmed death 1 ligand 1) therapies are most widely applied in clinical practice. Still, immune checkpoint inhibitors therapy is not always successful, and multiple studies have indicated that it should be combined with other immunotherapeutic strategies, including cytokines. Secreted cyclophilin A (CypA) could be of particular interest in this respect. Previously, we showed that recombinant human CypA (rhCypA) had pleiotropic immunostimulatory activity and anti-tumor effects. Studies of rhCypA as an anti-cancer factor pointed to its potential use in cancer chemoimmunotherapy and combination immunotherapy.
Aim. To evaluate anti-tumor effects of combined immunotherapy using rhCypA and immune checkpoint inhibitors in the mouse model of melanoma B16 in vivo.
Materials and methods. C57BL/6 mice were subcutaneously transplanted with melanoma B16. On days 6 and 9 posttumor transplantation, monoclonal antibodies to PD-1, PD-L1 and programmed cell death 1 ligand 2 (PD-L2), CTLA-4, lymphocyte-activation gene 3 (LAG-3), or CD276 were intravenously injected into mice at a dose of 100 μg/mouse. RhCypA was injected s/c on days 6–10 post-tumor transplantation at a dose of 100 μg/mouse. The therapeutic effects of combined immunotherapy were evaluated by melanoma B16 growth dynamics and the survival of tumor-bearing mice.
Results. In combination with anti-CTLA-4 monoclonal antibodies, rhCypA had the most distinct and prolonged synergic anti-tumor effects until day 19 post-immunotherapy, with an increase in animal lifespan of 70 %. When used with anti-LAG-3 monoclonal antibodies, rhCypA exhibited a synergic therapeutic effect by day 12 post-therapy. Combination of rhCypA with anti-PD-L1 or anti-CD276 monoclonal antibodies had short-term synergic effects until day 5 after therapy. Recombinant human CypA impeded the anti-tumor effects of dual anti-PD-1 + anti-LAG-3 therapy.
Conclusion. Our findings pointed out that rhCypA could significantly improve therapeutic effects of individual immune checkpoint inhibitors. Therefore, rhCypA could be potentially proposed as a component of combined anti-tumor immunotherapy.

1. Rui R., Zhou L., He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol 2023;14:1212476. DOI: 10.3389/fimmu.2023.1212476

2. Ren X., Guo S., Guan X. et al. Immunological classification of tumor types and advances in precision combination immunotherapy. Front Immunol 2022;13:790113. DOI: 10.3389/fimmu.2022.790113

3. Tsimberidou A.M., Fountzilas E., Nikanjam M., Kurzrock R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev 2020;86:102019. DOI: 10.1016/j.ctrv.2020.102019

4. Toor S.M., Sasidharan Nair V., Decock J., Elkord E. Immune checkpoints in the tumor microenvironment. Semin Cancer Biol 2020;65:1–12. DOI: 10.1016/j.semcancer.2019.06.021

5. Jia H., Yang H., Xiong H., Luo K.Q. NK cell exhaustion in the tumor microenvironment. Front Immunol 2023;14:1303605. DOI: 10.3389/fimmu.2023.1303605

6. Sanchez-Correa B., Lopez-Sejas N., Duran E. et al. Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy. Cancer Immunol Immunother 2019;68(5):861–70. DOI: 10.1007/s00262-019-02336-6

7. Wang L., Geng H., Liu Y. et al. Hot and cold tumors: Immunological features and the therapeutic strategies. MedComm 2020;4(5):e343. DOI: 10.1002/mco2.343

8. Webb E.S., Liu P., Baleeiro R. et al. Immune checkpoint inhibitors in cancer therapy. J Biomed Res 2018;32(5):317–26. DOI: 10.7555/JBR.31.20160168

9. Naidoo J., Page D.B., Li B.T. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26(12):2375–91. DOI: 10.1093/annonc/mdv383

10. Alsaab H.O., Sau S., Alzhrani R. et al. PD1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 2017;8:561. DOI: 10.3389/fphar.2017.00561

11. Khair D.O., Bax H.J., Mele S. et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front Immunol 2019;10:453. DOI: 10.3389/fimmu.2019.00453

12. Wang Y., Wang Y., Ren Y. et al. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Semin Cancer Biol 2022;86(Pt. 3):542–65. DOI: 10.1016/j.semcancer.2022.02.010

13. Zhou W.T., Jin W.L. B7-H3/CD276: an emerging cancer immunotherapy. Front Immunol 2021;12:701006. DOI: 10.3389/fimmu.2021.701006

14. Albrecht L.J., Livingstone E., Zimmer L., Schadendorf D. the latest option: nivolumab and relatlimab in advanced melanoma. Curr Oncol Rep 2023;25(6):647–57. DOI: 10.1007/s11912-023-01406-4

15. Duan Q., Zhang H., Zheng J., Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 2020;6(7):605–18. DOI: 10.1016/j.trecan.2020.02.022

16. Mehdi A., Attias M., Mahmood N. et al. Enhanced anticancer effect of a combination of s-adenosylmethionine (SAM) and immune checkpoint inhibitor (ICPi) in a syngeneic mouse model of advanced melanoma. Front Oncol 2020;10:1361. DOI: 10.3389/fonc.2020.01361

17. Berraondo P., Sanmamed M.F., Ochoa M.C. et al. Cytokines in clinical cancer immunotherapy. Br J Cancer 2019;120(1):6–15. DOI: 10.1038/s41416-018-0328-y

18. Bharadwaj U., Zhang R., Yang H. et al. Effects of cyclophilin A on myeloblastic cell line KG-1 derived dendritic like cells (DLC) through p38 MAP kinase activation. J Surg Res 2005;127(1):29–38. DOI: 10.1016/j.jss.2005.02.020

19. Xu Q., Leiva M.C., Fischkoff S.A. et al. Leukocyte chemotactic activity of cyclophilin. J Biol Chem 1992;267(17):11968–71.

20. Dawar F.U., Xiong Y., Khattak M.N.K. et al. Potential role of cyclophilin A in regulating cytokine secretion. J Leukoc Biol 2017;102(4):989–92. DOI: 10.1189/jlb.3RU0317-090RR

21. Kalinina A., Golubeva I., Kudryavtsev I. et al. Cyclophilin A is a factor of antitumor defense in the early stages of tumor development. Int Immunopharmacol 2021;9:107470. DOI: 10.1016/j.intimp.2021.107470

22. Kalinina A., Silaeva Y., Kazansky D., Khromykh L. The role of recombinant human cyclophilin a in the antitumor immune response. Acta Naturae 2019;11(2):63–7. DOI: 10.32607/20758251-2019-11-2-63-67

23. Kalinina A., Kazansky D., Khromykh L. Recombinant human cyclophilin A in combination with adoptive T-cell therapy improves the efficacy of cancer immunotherapy in experimental models in vivo. Biochemistry (Moscow) 2023;88:590–9. DOI:10.1134/S0006297923050024

24. Kalinina A., Kolesnikov A., Kozyr A. et al. Preparative production and purification of recombinant human Cyclophilin A. Biochemistry (Moscow) 2022;87:259–68. DOI: 10.1134/S0006297922030063

25. Guidelines for pre-clinical drug evaluations. Pt. 1. Ed. by A.N. Mironov. Moscow: Grif i K, 2012. 944 p. (In Russ.).

26. Ma J., Yan S., Zhao Y. et al. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells. Front Immunol 2023;14:1265255. DOI: 10.3389/fimmu.2023.1265255

27. Woo S.R., Turnis M.E., Goldberg M.V. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72(4):917–27. DOI: 10.1158/0008-5472.CAN-11-1620

28. Wei Y., Li Z. LAG3-PD-1 Combo overcome the disadvantage of drug resistance. Front Oncol 2022;12:831407. DOI: 10.3389/fonc.2022.831407

29. Ji S., Lee J., Lee E.S. et al. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Hum Vaccin Immunother 2021;17(7):1910–22. DOI: 10.1080/21645515.2020.1866951

30. Singh M., Khong H., Dai Z. et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol 2014;193(9):4722–31. DOI: 10.4049/jimmunol.1401160

31. Garcia M.G., Deng Y., Murray C. et al. Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. Aging Cancer 2022;3(1):68–83. DOI: 10.1002/aac2.12045

32. Iwai Y., Ishida M., Tanaka Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293–7. DOI: 10.1073/pnas.192461099

33. Dutta S., Ganguly A., Chatterjee K. et al. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology (Basel) 2023;12(2):218. DOI: 10.3390/biology12020218

34. He Y., Rivard C.J., Rozeboom L. et al. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci 2016;107(9):1193–7. DOI: 10.1111/cas.12986